RxSight Reports Strong Q1 Growth Amid Market Challenges

Introduction

RxSight, Inc. is an ophthalmic medical technology company headquartered in Aliso Viejo, California. Founded in 1997, the firm developed and commercialized the Light Adjustable Lens (LAL), the first and only intraocular lens that can be adjusted after cataract surgery. As of July 9, 2025, RxSight’s shares trade on the Nasdaq under the ticker RXST at $6.50 per share, reflecting a 49.18% decline year-to-date, with a daily volume of 1,942,244 shares exchanged.

Corporate Structure

RxSight employs between 201 and 500 people across research and development, manufacturing, sales, and clinical support. The executive team is led by President and CEO Dr. Kurtz (in position since 2016), Chief Commercial Officer Mr. Weinberg, Chief Operating Officer Dr. Goldshleger, and Chief Financial Officer Ms. Thunen. Operations are centered in Aliso Viejo, with clinical training and service centers located throughout the United States and in select international markets.

Light Adjustable Lens by Alexander Andrews

Developments and News

• May 7, 2025: RxSight reported first-quarter 2025 results for the period ended March 31, 2025. Revenue was $37.9 million, an increase from $29.5 million in Q1 2024, driven by a 36% rise in LAL procedure volume (27,579 lenses sold) and an 8% increase in Light Delivery Device (LDD) sales. The installed base of LDD units expanded to 1,044 devices, up 43% year-over-year.
• July 8, 2025: The company filed an 8-K (items 2.02 and 9.01), disclosing corporate updates and compliance matters.
• June 4, 2025: An 8-K (item 5.07) was submitted, although it did not include material financial metrics.
• May 20, 2025: RxSight filed its annual Specialized Disclosure report (Form SD), outlining sustainability and supply chain practices.
• Clinical data published on the company website show that in a 12-month, multicenter study of 600 patients, 92% of eyes implanted with the LAL achieved a manifest refraction within 0.50 diopters of target six months post-operatively.

Financial and Strategic Analysis

In Q1 2025, gross profit rose to $28.3 million (74.8% of revenue) from $20.7 million (70.1%) in Q1 2024, reflecting lower production costs and a favorable shift toward LAL sales. Operating expenses were $39.0 million, up 24% from $31.4 million, as the company invested in expanding its installed base and advancing its R&D pipeline. The net loss narrowed to $8.2 million (or $0.20 per share) compared with a $9.1 million loss (or $0.25 per share) in Q1 2024. Adjusted net loss improved to $1.1 million (or $0.03 per share) versus $4.4 million (or $0.12 per share). Cash and equivalents totaled $229.3 million as of March 31, 2025, down $7.9 million from December 31, 2024.

For full-year 2025, RxSight reaffirmed guidance calling for revenue of $160 million to $175 million (14% to 25% growth), gross margin of 71% to 73%, and operating expenses of $150 million to $160 million (including $27 million to $30 million in stock-based compensation).

Strategically, RxSight is expanding third-party service center models for light treatments, pursuing additional international regulatory approvals, and investing in its R&D pipeline. Collaborations with cataract surgeons and optometrists support the adoption of the LAL in premium IOL procedures.

Market Position and Industry Context

RxSight competes in the premium intraocular lens market alongside manufacturers such as Alcon and Johnson & Johnson Vision. Its Light Adjustable Lens differentiates itself by enabling postoperative refractive adjustments, a capability not available with conventional monofocal or multifocal lenses. The global cataract surgery market is driven by aging demographics, and customization along with post-operative adjustability are increasingly valued by surgeons and patients. With an expanding installed base of LDD units and rising procedure volumes, RxSight aims to capture a larger share of the premium IOL segment in the U.S. and key international markets, including South Korea.

tl;dr

On May 7, 2025, RxSight reported Q1 revenue of $37.9 million (up 28% year-over-year), driven by a 36% increase in Light Adjustable Lens volume and a 43% expansion in Light Delivery Device installations. Gross margin rose to 74.8%; net loss narrowed to $8.2 million, with adjusted net loss improving to $1.1 million. Cash reserves were $229.3 million. Full-year 2025 guidance remains $160 million to $175 million in revenue, 71% to 73% gross margin, and $150 million to $160 million in operating expenses. Key initiatives include expanding third-party light treatment services, pursuing international approvals, and advancing the R&D pipeline.